Corporate & Commercial

In a November 2009 speech before the Tenth Annual Pharmaceutical Regulatory and Compliance Congress in Washington D.C., Assistant Attorney General Lanny A. Breuer put big pharma on notice that DOJ intended to aggressively investigate potential violations of the FCPA within the pharmaceutical and medical device industry.  The DOJ’s FCPA team appears to be backing that

In a detailed, 122-page opinion (pdf), U.S. District Court Judge John G. Koeltl systematically dismantled and dismissed the SEC’s first-ever credit default swap insider trading case.  In SEC  v. Jon-Paul Rorech and Renato Negrin (pdf), the SEC alleged that Deutsche Bank bond salesman, Jon-Paul Rorech, passed material, non-public information to a Millennium Partners hedge

There is good reason, beyond anger, voyeurism and schadenfreude, for Wall Street and “Main Street” to keep their eyes on the SEC enforcement action against investment banking firm Goldman Sachs & Co and one of its vice presidents, Fabrice Tourre
According to the SEC’s complaint (pdf), Goldman was paid by one of the world’s largest hedge

You need to follow along closely because this can get a bit confusing.  As we all recall, in 2003, judgments were entered against 12 of the largest Wall Street firms that issued research and engaged in investment banking, commonly referred to as “The Global Settlement.”  The Global Settlement imposed significant restrictions on interactions between the